ACCF/AHA 2007 Clinical Competence Statement on Vascular Imaging With Computed Tomography and Magnetic Resonance

A Report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training

Developed in Collaboration With the Society of Atherosclerosis Imaging and Prevention, the Society for Cardiovascular Angiography and Interventions, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society for Vascular Medicine and Biology

Writing Committee Members

Christopher M. Kramer, MD, FACC, FAHA, Chair
Matthew J. Budoff, MD, FACC, FAHA*
Zahi A. Fayad, PhD, FACC, FAHA†
Victor A. Ferrari, MD, FACC
Corey Goldman, MD, PhD, FACP, FSVMB‡
John R. Lesser, MD, FACC
Edward T. Martin, MD, FACC, FACP, FAHA
Sanjay Rajagopalan, MD, FACC§
John P. Reilly, MD, FACC, FSCAI¶
George P. Rodgers, MD, FACC
Lawrence Wechsler, MD, FAHA

* Society of Cardiovascular Computed Tomography Representative;
† Society of Atherosclerosis Imaging and Prevention Representative;
‡ Society for Vascular Medicine and Biology Representative;
§ Society for Cardiovascular Magnetic Resonance Representative;
¶ Society for Cardiovascular Angiography and Interventions Representative

TABLE OF CONTENTS

Preamble ........................................................................................................... 1098

Introduction ..................................................................................................... 1099

Vascular CT ....................................................................................................... 1099

Cognitive Knowledge Required for Competency ........................................... 1099

1. Hardware ........................................................................................................ 1099

2. Acquisition Techniques .............................................................................. 1100

3. Image Processing and Interpretation ......................................................... 1100

4. Contrast Agents .......................................................................................... 1100

5. Radiation Dosimetry .................................................................................. 1100

6. Specific Applications .................................................................................. 1101

A. Aorta ............................................................................................................. 1101

B. Upper Extremity Arteries .......................................................................... 1101

C. Extracranial Cerebrovascular Arteries ...................................................... 1101

D. Pelvic and Lower Limb Arteries ................................................................. 1102

E. Renal Arteries ............................................................................................. 1102

F. Mesenteric Arteries ................................................................................... 1102

G. CT Venography .......................................................................................... 1103

H. Other ........................................................................................................... 1103

Formal Training and Competence in Vascular CT ......................................... 1103

1. Formal Fellowship ....................................................................................... 1103

2. Alternative Pathways .................................................................................. 1104

Maintaining Expertise in Vascular CT ............................................................. 1104

This document was approved by the American College of Cardiology Foundation Board of Trustees in June 2007 and by the American Heart Association Science Advisory and Coordinating Committee in July 2007. When citing this document, the American College of Cardiology Foundation and the American Heart Association request that the following citation format be used: Kramer CM, Budoff MJ, Fayad ZA, Ferrari VA, Goldman C, Lesser JR, Martin ET, Rajagopalan S, Reilly JP, Rodgers GP, and Wechsler L. ACCF/AHA clinical competence statement on vascular imaging with computed tomography and magnetic resonance: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training. J Am Coll Cardiol 2007;50:1097–114.

This article has been copublished in the September 11, 2007, issue of Circulation. Copies: This document is available on the World Wide Web sites of the American College of Cardiology (www.acc.org), and the American Heart Association (www.americanheart.org). For copies of this document, please contact Elsevier Inc. Reprint Department, fax (212) 633-3820, e-mail reprints@elsevier.com.

Permissions: Modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American College of Cardiology Foundation or the American Heart Association. Please contact the American Heart Association: Instructions for obtaining permission are located at http://www.americanheart.org/presenter.jhtml?identifier=4431. A link to the “Permission Request Form” appears on the right side of the page.
The granting of clinical staff privileges to physicians is a primary mechanism used by institutions to uphold the quality of care. The Joint Commission on Accreditation of Healthcare Organizations requires that the granting of continuing medical staff privileges be based on assessments of applicants against professional criteria specified in the medical staff bylaws. Physicians themselves are thus charged with identifying the criteria that constitute professional competence and with evaluating their peers accordingly. Yet, the process of evaluating physicians’ knowledge and competence is often constrained by the evaluator’s own knowledge and ability to elicit the appropriate information, problems compounded by the growing number of highly specialized procedures for which privileges are requested.

The American College of Cardiology Foundation (ACCF)/American Heart Association (AHA)/American College of Physicians (ACP) Task Force on Clinical Competence and Training was formed in 1998 to develop recommendations for attaining and maintaining the cognitive and technical skills necessary for the competent performance of a specific cardiovascular service, procedure, or technology. These documents are evidence-based, and where evidence is not available, expert opinion is utilized to formulate recommendations. Indications and contraindications for specific services or procedures are not included in the scope of these documents. Recommendations are intended to assist those who must judge the competence of cardiovascular health care providers entering practice for the first time and/or those who are in practice and are undergoing periodic review of their practice expertise. The assessment of competence is complex and multidimensional; therefore, isolated recommendations contained herein may not necessarily be sufficient or appropriate for judging overall competence. The current document addresses competence in vascular imaging for computed tomography (CT) and magnetic resonance (MR) and is authored by representatives of the ACCF, the AHA, the Society of Atherosclerosis Imaging and Prevention (SAIP), the Society for Cardiovascular Angiography and Interventions (SCAI), the Society of Cardiovascular Computed Tomography (SCCT), the Society for Cardiovascular Magnetic Resonance (SCMR), and the Society for Vascular Medicine and Biology (SVMB).

The ACCF/AHA/ACP Task Force makes every effort to avoid any actual or potential conflicts of interest that might arise as a result of an outside relationship or a personal interest of a member of the ACCF/AHA/ACP Writing Committee. Specifically, all members of the Writing Committee are asked to provide disclosure statements of all such relationships that might be perceived as real or potential conflicts of interest relevant to the document topic. These are reviewed by the Writing Committee and updated as changes occur. The relationships with industry information...
for authors and peer reviewers are published in the appendices of the document.

Mark A. Creager, MD, FACC, FAHA
Chair, ACCF/AHA/ACP Task Force on Clinical Competence and Training

Introduction

This statement is the first American College of Cardiology (ACC)/AHA document on clinical competence in vascular computed tomography (CT) and magnetic resonance imaging (MRI) and is designed to assist in the assessment of physicians’ competence on a procedure-specific basis. The minimum experience, knowledge base, and technical skills necessary for the competent performance of vascular CT and MRI are specified. These represent the minimum experience requirements for the assessment of competence in these disciplines (or procedures) in the broadest sense. Whenever possible, the specifications are primarily based on consensus of expert opinion in the absence of extensive literature that links these factors with competence. The specifications are applicable to different practice settings and training backgrounds and can accommodate a number of ways in which physicians can demonstrate competence in the performance of specific procedures. Expertise in the performance of these procedures in patients with infrequently encountered diagnoses or of less commonly performed variations of standard procedures may require additional experience or training. Therefore, it is expected that even highly competent practitioners will occasionally benefit from consultation with colleagues who have even more highly specialized interests, experience, or skills. Due to the quantity and complexity of nonvascular findings that may be imaged with either technique, competence in imaging and interpretation of these findings is beyond the scope of this document.

This document addresses physicians who have already completed a formal training program and is not meant to encompass the training requirements for performing vascular MRI and CT. The process of acquiring these skills is different once one has completed a formal training program. Training guidelines will be covered in the latest edition of Core Cardiology Training (COCATS) for cardiology trainees and in other documents put forth by other societies (1).

In addition to members of the ACCF and the AHA, the Writing Committee included representatives of the SAIP, the SCAI, the SCCT, the SCMR, and the SVMB. Representation by an outside organization does not necessarily imply endorsement. In addition to content peer reviewers, “official” reviewers were provided by the ACC and the AHA. This document was approved for publication by the governing bodies of the ACC and the AHA. In addition, the governing boards from the SAIP, the SCAI, the SCCT, the SCMR, and the SVMB formally endorsed this document.

Vascular CT

Cognitive Knowledge Required for Competency

1. Hardware

Physicians interested in computed tomographic angiography (CTA) should have knowledge of advances in CT hardware (Table 1) which have accelerated since the introduction of axial CT in 1973. Starting with a rotating gantry incorporating an X-ray source, there have been progressive increases in the number of detector elements (2). Advances over the last decade include table translation simultaneous with rotation of a gantry incorporating an X-ray source with extended longitudinal or z-axis coverage. Thus, images can be reconstructed at any position along the patient axis (longitudinal or z-axis), and overlapping image reconstruction is used to improve longitudinal resolution (3). The introduction of 16-slice CT in 2003 marked the arrival of technology to assess all vascular territories including the lower extremities using detectors that were 0.75 mm or less in width. The 64-slice CT systems introduced in 2004 have resulted in further reductions in gantry rotation times to 330 to 420 ms and improved performance of electrocardiographic (ECG)-referenced scanning. Dual-source CT scan-
planes. Curved multiplanar reformats (CMPR) trace a
angiogram in two-dimensional (2D) planes and, thus, cannot be completely displayed by
computer workstation console. Arterial anatomy traverses post-processing techniques which are performed at the
practitioner of CTA should also be comfortable with
Evaluation of the available source images is essential. The
administration will be determined by the iodine concentra-
tsion. The volume, duration, and injection rate of contrast
parameters (4). Intravenous administration of an iodinated
region of interest for which the CTA has been requested
sion is beyond the scope of this statement. In general, the
brand and capability of the scanner; a complete discus-
sion and continuous data acquisition while the patient table
is moving at a constant speed.

2. Acquisition Techniques
Physicians must demonstrate competence in the techniques
required in the acquisition and interpretation of a CTA
Specific acquisition techniques will be determined by the brand and capability of the scanner; a complete discus-
sion is beyond the scope of this statement. In general, the
region of interest for which the CTA has been requested and the scanner capacity will determine the scan acquisition
parameters (4). Intravenous administration of an iodinated contrast medium must be synchronized with image acquisi-
tion. The volume, duration, and injection rate of contrast
administration will be determined by the iodine concentra-
tion of the contrast and the duration of the scan (5). Physicians performing CTA must demonstrate an under-
standing of the factors that determine contrast transit times and the available means to accurately synchronize contrast
administration and scanning. Candidates must understand the relative merits and limitations of both timing bolus and
automated bolus monitoring techniques (6). Practitioners of
CTA should understand the necessary adjustments in ac-
quision techniques for imaging pediatric patients, obese
patients, patients that cannot raise their arms, and uncoop-
erative patients.

3. Image Processing and Interpretation
MDCT acquires hundreds to thousands of axial images (7).
Evaluation of the available source images is essential. The
practitioner of CTA should also be comfortable with post-
processing techniques which are performed at the
computer workstation console. Arterial anatomy traverses
multiple planes and, thus, cannot be completely displayed by
axial or any other single projection. Multiplanar reformats
(MPR) present the angiogram in two-dimensional (2D)
planes. Curved multiplanar reformats (CMPR) trace a
to facilitate understanding of the terms used in the
subsequent sections of this report but is not intended to
be comprehensive.

The MDCT design has evolved through successive iter-
ations. In its simplest form, a modern MDCT scanner
comprises an X-ray source, rotating gantry, pre- and post-
detector collimators, and detector arrays. The detector
assembly comprises several rows of detector elements that
typically cover a scan field of view of approximately 50 cm.
The attenuation data (after passing from the source, through the body, and incident on the detector array) are
recorded and transformed through filtered back-projection
into the CT image. Axial or sequential scanning is the
simplest and oldest technique for acquiring data. Helical/
spiral scanning is characterized by continuous gantry rota-
tion and continuous data acquisition while the patient is
moving at a constant speed.

4. Contrast Agents
Aside from exposure to ionizing radiation, iodinated con-
trast material is the most significant risk of CTA. Contrast-
induced nephropathy (CIN) is the third most common
cause of acute renal failure among hospitalized patients (8).
Physicians who wish to perform CTA must recognize that
the presence of diabetes mellitus, pre-existing renal insuffi-
ciency, congestive heart failure, and recent contrast exposure
can significantly increase the risk of CIN (9–11). Practitioners
must understand measures that may offer some protection
against CIN such as hydration, discontinuation of nephro-
toxic drugs, and the use of nonionic, iso-osmolar contrast
agents (12–15). Severe anaphylactic reactions to contrast
material are seen in 0.04% to 0.22% of procedures and can
be life threatening (16). Less severe allergic reactions are
more commonly observed (17). Physicians performing CTA
must be well acquainted with the treatment of cardiovascu-
lar collapse due to anaphylactic allergic reactions as well as
to less severe reactions. They also must understand how to
use prophylactic therapy prior to contrast administration in
patients with a previous history of allergic response. They
should consider a recommendation of alternative testing in
those with a history of significant allergic reaction.

5. Radiation Dosimetry
Although ionizing radiation from natural sources is part of
our daily existence, it is mandatory that practitioners of
CTA understand the potential risks of ionizing radiation
exposure from the test and balance these risks against the
potential benefits. Health care professionals must have an
understanding of the exposure involved in MDCT applica-
tions that image the vasculature and to effectively advise
candidates for imaging. Patient doses for MDCT acquisition should be set at the lowest values that are consistent with satisfactory image quality. Most physicians seeking training in CTA applications will likely have had some didactic teaching regarding radiation physics during their training. However, specific instruction to keep radiation exposure as low as possible when performing MDCT may be additionally required. In general, there are differences in radiation exposure depending on the vascular application. Adoption of the effective dose as a standard measure of biologic risk allows comparability across the spectrum of medical and nonmedical exposures. The effective dose is, by definition, an estimate of the uniform, whole-body equivalent dose that would produce the same level of risk of adverse effects as from nonuniform partial body irradiation. The unit for the effective dose is the milliSievert (mSv) (www.fda.gov/cdrh/ct/rqu.html). Typical values for the effective patient dose of selected CT protocols are 1 to 2 mSv for a head examination, 6 to 14 mSv for noncoronary CTA of the chest, and 8 to 16 mSv for CTA of the abdomen, pelvis, and lower extremities, depending on patient and scanner variables that may include dose-reduction strategies (18–23). The effective dose of retrospective ECG-gated exams is much higher than that of nongated exams. This radiation exposure must be appreciated in the context of the average annual background radiation, which is 2 to 5 mSv (average = 3.6 mSv in the United States).

Axial/sequential techniques require less radiation and could be used for clinical indications that are least compromised by motion artifacts. In helical/spiral MDCT, which is more commonly used for chest angiography, the dose can be reduced by 30% to 50% by using ECG-controlled dose-modulation techniques. Another approach relevant to clinical practice is anatomic tube current modulation where the tube output is adapted to the patient geometry during each rotation of the scanner to compensate for strongly varying X-ray attenuations in asymmetric regions such as the shoulders and pelvis (24). The radiation dose increases with thinner slices (because tube current is typically increased to maintain image noise) and smaller pitch (more overlapping images). Another means to reduce radiation dose is to adapt the X-ray tube voltage to the intended application. Patient dose can be reduced by choosing lower kVp settings. A recent study reports a dose savings of 30% without a loss of diagnostic information with 100 kVp when evaluating the aorta and iliac arteries (22). This approach, however, may not be appropriate for obese patients because penetration of X-rays decreases with decreasing tube voltage.

6. Specific Applications

A. AORTA
The practitioner of CTA should be knowledgeable about the utility of conventional CT scanning for diagnosing thoracic aortic aneurysms and dissections (25,26). The knowledge required to perform aortic CTA includes the ability to diagnose aortic dissection, which can be identified with greater than 95% accuracy. Excellent definition of the intimal flap, false and true lumens, and the amount of intra-aneurysmal thrombus can be determined. Practitioners of CTA should understand its use for diagnosing aortic aneurysm, defining its maximal diameter, and monitoring its expansion over time (27). Recognition of the use of CTA to diagnose traumatic aneurysms of the thoracic aorta, sinus of Valsalva aneurysms, and coarctation of the aorta is important. The diagnosticians should understand the potential advantages of CTA in patients undergoing “redo” coronary artery bypass surgery (28). CTA may guide the surgical approach by defining the position of the sternum to the right ventricle, existing grafts, and aorta and thereby avoid unnecessary complications. The imager should recognize that the presence of severe aortic plaque raises the risk of stroke during “redo” surgery.

B. UPPER EXTREMITIES
There is limited clinical data on the utility and performance of CTA for the diagnosis and management of upper extremity arterial disease (29,30). CTA of upper extremity arterial disease requires knowledge of variant anatomy of the arch vessels including aberrant origins. Subclavian artery stenosis from a number of diseases, including atherosclerosis and vasculitis, can be effectively diagnosed using CTA. An understanding of the role of CTA in the diagnosis and management of subclavian and axillary aneurysms is essential. CTA allows accurate measurements of the diameter of the area to be treated as well as the length of the appropriate endograft. CTA can also be utilized for post-intervention surveillance to assess for endoleaks or deformity of the device. Recognition of the etiology and anatomic location of the ischemic upper extremity is crucial to those who wish to practice CTA. Common causes include atherosclerotic disease, embolism (cardiac and vascular sources including thoracic outlet syndrome), and vasculitis. CTA can provide important information on the anatomy of the thoracic outlet; angiography with provocative maneuvers can be helpful in establishing the diagnosis.

An understanding of the potential involvement of the upper extremity in up to 40% of extremity-penetrating trauma is important for CTA interpreters (31). Trauma can also result in vascular spasm, an intimal tear, pseudoaneurysm, arteriovenous fistula, or occlusion. CTA surveillance of hemodialysis access should be understood by those who perform the procedure. Because there is no concern for exacerbating renal dysfunction with iodinated contrast administration in hemodialysis patients, CTA offers a rapid, high spatial resolution study to assess graft patency and arterial inflow and venous outflow.

C. EXTRACRANIAL CEREBROVASCULAR ARTERIES
Practitioners should recognize that the use of CTA is rapidly increasing for vascular evaluation in patients with suspected cerebrovascular disease. CT is often the initial test in patients with transient ischemic attack (TIA) or stroke to exclude hemorrhage and to detect early changes associated
with ischemia. CTA can be added to a CT examination, adding only 5 to 10 min to the study and providing real anatomic detail. CTA measurements of percent stenosis show a high correlation with digital subtraction angiography (DSA) (32) and in fact, 3D reconstructions of the carotid often permit a more complete assessment of eccentric lesions. An understanding that calcification interferes with CTA is crucial, particularly in complex calcified plaques where the degree of stenosis may not be adequately assessed. Segments of the carotid parallel to the plane of imaging are subject to flow effects, and stenosis of these regions may be artifactual. Knowledge of the strengths, weaknesses, and potential pitfalls of CTA imaging is essential to appropriate and accurate interpretation.

An understanding of the pathophysiological processes that affect the cerebral arteries is also important. Atherosclerosis is the most common cause of arterial narrowing and typically occurs at the carotid bifurcation in the neck, at the origin from the aortic arch, and in the intracranial segment at the level of the carotid siphon (33). Practitioners of CTA should be able to recognize other pathologies such as dissection, intraluminal thrombus, vasculitis, or vasospasm that may appear similar on CTA but should be distinguished by the clinical setting and anatomic characteristics. Knowledge of the clinical features of diseases that affect the cerebral circulation is necessary for optimal interpretation of CTA. In addition, recognition of symptoms attributable to the carotid and basilar circulation is important to focus interpretation on the clinically relevant arterial segments.

Knowledge of the different types of cerebral aneurysms is essential to physicians performing CTA, as CTA can readily define their size, length, and diameter. A thorough understanding of the appearance and distribution of arterial dissection is important to the proper identification and interpretation of CTA. Traumatic injury to the carotid artery commonly results in dissection. CTA practitioners should know that CTA may demonstrate a small irregular lumen even when other studies such as magnetic resonance angiography (MRA) or carotid ultrasound suggest occlusion (34,35).

D. PELVIC AND LOWER LIMB ARTERIES
It should be understood that a complete acquisition of lower extremity inflow and run-off is presently available with MDCT angiography that was not previously available with fewer detectors (36). The increase in spatial resolution now afforded by CTA allows the differentiation between high- and low-grade stenoses in peripheral vasculature, and the characterization of the nature of the lesion, differentiating atheromatous from thrombotic stenoses (37). CTA practitioners should understand that it has been shown to have excellent correlation with DSA (38–40). Limitations of CTA include the presence of dense calcifications and endoluminal stents, which may impair the quantification of the degrees of peripheral arterial disease (PAD).

Practitioners must demonstrate a thorough knowledge of arterial pathophysiology and its clinical presentation. Knowledge of just atherosclerotic disease is not sufficient. Competency also requires an understanding of inflammatory and aneurysmal diseases, thromboembolic disease, vascular injury, spontaneous and iatrogenic dissections, and congenital abnormalities. The capacity of CTA to visualize the arterial wall, as well as the lumen, provides the interpreter a greater degree of certainty when arriving at less common diagnoses. The relationship and effect of other anatomic structures on the vasculature must be understood, such as compression of venous structures by pelvic tumors resulting in stasis and thrombosis or dynamic compression of an entrapped popliteal artery. Knowledge of the potential utility of CTA in the evaluation of graft patency is important as well as in the detection of graft-related complications (graft stenosis, aneurysmal changes, and arteriovenous fistulas). Practitioners of CTA should recognize the value of CTA in the setting of peripheral vascular trauma in the assessment of complicated or partial occlusions, arteriovenous fistulae, intimal flaps, and pseudoaneurysms (31).

E. RENAL ARTERIES
The knowledge required to perform CTA of the renal arteries includes an understanding of the normal anatomy and its common variations such as accessory renal branches and familiarity with vascular anomalies and the usual location and appearance of a transplanted kidney (41). The diagnostician should be cognizant of the various etiologies of renal artery stenosis, including atherosclerosis, fibromuscular dysplasia, and other causes of renovascular disease such as polyarteritis nodosa, arteriovenous fistulae, aneurysms, thrombosis, and embolism. Identification of renal parenchymal enhancement patterns identifying the cortex, medulla, and the collecting system is important for the recognition of intrinsic parenchymal disease. The interpreter should be capable of relating renal CTA findings with results of other diagnostic imaging modalities, particularly duplex ultrasonography and MRA.

F. MESENTERIC ARTERIES
CTA of the mesenteric arteries requires knowledge of the normal anatomy of the celiac artery, superior mesenteric artery, and inferior mesenteric artery as well as the common variants and collaterals such as pancreaticoduodenal collaterization and the marginal artery of Drummond, a collateral vessel to the superior mesenteric artery. The expert should be cognizant of the etiologies and pathophysiology of mesenteric ischemia such as atherosclerosis, arterial thrombosis or embolism, vasculitis, celiac trunk compression from the median arcuate ligament, and mesenteric vein thrombosis (41). The CTA specialist should recognize the clinical manifestations of mesenteric ischemia and be knowledgeable about the indications for endovascular and surgical therapies for both acute and chronic mesenteric ischemia.
G. CT VENOGRAPHY

The practitioner of CTA should understand the use of peripheral venous CT for demonstrating deep venous thrombosis (DVT), especially the proximal extent into the iliac vein or inferior vena cava (IVC) (42). CT venography provides direct imaging of the IVC, pelvic and lower extremity veins immediately after CT of the pulmonary arteries without injection of additional contrast material, adding only a few minutes to the examination. The diagnostician should be aware that because DVT is the most important factor predisposing to pulmonary embolism (PE), a single examination capable of evaluating both the pulmonary arterial system and the pelvic and lower extremity venous system may offer advantages over other tests directed at either diagnosis alone (43). Practitioners should understand that adding CT venography to CTA increases the sensitivity for PE without reducing specificity (44).

Knowledge of the use of CT venography in the evaluation of venous thrombosis involving the upper extremity veins (brachiocephalic and axillary veins) is important, especially in cases of suspected venous thrombosis due to malignancies (Malignant Superior Vena Cava Syndrome) (45). Owing to the superior discriminatory properties of CT for lung parenchyma over MRI, CT venography in conjunction with CT of the chest is the diagnostic study of choice for this type of evaluation. The expert should be capable of identifying venous contrast mixing artifacts commonly seen in standard renal CTA in relation to discerning renal vein thrombosis. The limitations of CTA for identifying mesenteric venous thrombosis should be appreciated, and the predicted locations of mesenteric and portal veins should be included in the expert’s knowledge base.

H. OTHER

The previous list is not meant to be exhaustive. There may be other organ-specific applications, such as arteriovenous malformations, which are not specifically addressed.

Table 2. Cognitive Skills Required for Competence in Vascular CT

<table>
<thead>
<tr>
<th>Knowledge</th>
<th>Cognitive Skills</th>
</tr>
</thead>
<tbody>
<tr>
<td>General</td>
<td>Physics of CT and radiation generation and exposure</td>
</tr>
<tr>
<td></td>
<td>Scanning principles and scanning modes for noncontrast- and contrast-enhanced vascular imaging</td>
</tr>
<tr>
<td></td>
<td>Principles of intravenous iodinated contrast administration for safe and optimal vascular imaging</td>
</tr>
<tr>
<td></td>
<td>Prevention, recognition, and treatment of adverse reactions to iodinated contrast</td>
</tr>
<tr>
<td>Vascular anatomy</td>
<td>Normal anatomy of the aorta, brachiocephalic, cerebrovascular, pelvic and lower extremity, renal, and mesenteric arteries</td>
</tr>
<tr>
<td></td>
<td>Normal anatomy of the SVC and IVC, cerebrovascular, pelvic, lower extremity, renal, and mesenteric veins</td>
</tr>
<tr>
<td>Vascular pathology</td>
<td>Congenital anomalies, aneurysm, dissection, occlusion, and stenosis, of the aorta, brachiocephalic, cerebrovascular, pelvic and lower extremity, renal, and mesenteric arteries</td>
</tr>
<tr>
<td></td>
<td>Thrombosis, compression, occlusion in and of the SVC and IVC, cerebrovascular, pelvic, lower extremity, renal, and mesenteric veins</td>
</tr>
<tr>
<td>Symptoms and signs of disease related to above vascular pathology</td>
<td></td>
</tr>
</tbody>
</table>

CT = computed tomography; IVC = inferior vena cava; SVC = superior vena cava.

Formal Training and Competence in Vascular CT

There are several potential pathways to achieve competence in vascular CT, including formal fellowship pathways and alternative pathways. The training achieved may allow a practitioner to either interpret or, depending on the expertise achieved, interpret and teach others the competencies in vascular CT. Cognitive skills required to demonstrate competence in vascular CTA are summarized in Table 2. All trainees will be required to demonstrate competence in the theoretical principles of CT imaging using MDCT technology. Candidates should receive didactic lectures from a qualified CT-trained physician and/or physicist on the basic physics of CT in general and of MDCT in particular. A thorough understanding of contrast injection methods, adverse events and their treatments, and contrast kinetics in patients will be required. In particular, knowledge is needed in appropriate bolus timing approaches that may be different for various vascular beds.

For those in cardiology fellowship training programs, specific training in vascular anatomy and physiology through dedicated vascular medicine training within the fellowship would be required. A thorough knowledge and understanding of vascular anatomy is required. Knowledge of characteristics of blood vessels in health and disease by traditional angiographic imaging methods (X-ray contrast angiography) provide a conceptual framework for application to CTA of the peripheral vessels. Basic concepts in vessel physiology are vital for an angiographer interpreting a stenosis in any vascular bed and basic training should be part of any formal training program.

1. Formal Fellowship

Formal training in vascular CT may be undertaken as part of cardiovascular fellowship (see the latest COCATS guidelines for cardiovascular computed tomography [CCT]) (1). The didactic training experience achieved should parallel...
that described in the COCATS recommendations for Level 2 trainees. Trainees should actively participate in daily CT study interpretation under the direction of a Level 2 or 3 (preferred) CCT-qualified physician. For all studies in which other vascular imaging data are available, such information should be correlated with CT data. This should include at least 50 cases of vascular CT, for which the trainee is present during the scan, ideally as the primary operator and the primary interpreter.

2. Alternative Pathways

Potential alternative pathways include spending at least 4 weeks with a practitioner of vascular CT who has the prior experience to train such an individual (Table 3). For those individuals who have achieved Level 2 or 3 training in cardiac CT, there is no specific time requirement. With either pathway, at least 50 cases of vascular CT should be performed to demonstrate competence, ideally for which the trainee is present during the scan and is the primary operator/interpreter. These cases should include the variety of cases as previously outlined. An additional 100 cases from teaching files, case studies, CDs/DVDs, or continuing medical education (CME) courses should also be reviewed.

Table 3. Alternative Pathways for Competence

<table>
<thead>
<tr>
<th>Pathway</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial experience*</td>
<td>• Level 2 or 3 CCT trained OR • 4 weeks of dedicated time with a qualified practitioner of vascular CT</td>
</tr>
<tr>
<td>Minimum number of mentored exams</td>
<td>• Mentored interpretation of 50 cases of vascular CT, ideally covering a broad range of vascular beds</td>
</tr>
<tr>
<td>Additional case reviews</td>
<td>• 100 cases of vascular CT from teaching files, case studies, CDs/DVDs, CME courses</td>
</tr>
</tbody>
</table>

*If one has obtained Level 2 or 3 competence in CCT, the time requirement is waived.

CCT = cardiovascular computed tomography; CME = continuing medical education; CT = computed tomography.

Because a physician’s practice or location may preclude this method, continued competency can also be assured through monitoring and evaluation that indicates acceptable technical success, accuracy of interpretation, and appropriateness of evaluation.

2. CME

Thirty hours of category I CME over 3 years in CCT or related fields are required to maintain expertise in vascular CT regardless of pathway.

Vascular MR

Cognitive Knowledge Required for Competency

1. Hardware and General Principles of MR

A brief overview of the technical aspects of cardiovascular magnetic resonance (CMR) as it applies to evaluation of blood vessels is included to facilitate the understanding of terms used in the subsequent sections of this report and is not intended to be comprehensive. The practitioner of vascular MR should comprehend the general principles of MR. Hardware used in an MR scanner are listed in Table 4.

The phenomenon of MR is restricted to atomic nuclei with unpaired spin such as hydrogen atoms (protons). In the presence of an external magnetic field, the hydrogen nucleus acts like a small magnet and aligns itself parallel to an external field, precessing about its axis in a manner analogous to a spinning top. The frequency of precession for hydrogen is 42.58 MHz/T, which corresponds to 63 MHz at a field strength of 1.5 T and 128 MHz at 3 T, and is in the radiofrequency (RF) range. Hydrogen nuclei can be excited by radio waves only at this resonant frequency (Larmor Frequency), which has the effect of rotating the net magnetization vector by an amount termed the “flip angle.” After this excitation, the net magnetization returns to its former position (relaxation) during which energy is transmitted as a radio signal and can be detected by a receiver coil. The return of the net magnetization vector to equilibrium has 2 components. The vector component parallel to
the main field relatively slowly returns to equilibrium by interacting with surrounding molecules; this is known as “T1 relaxation.” Recovery of the vector component transverse to the field is more rapid and is termed “T2 relaxation.” The CMR images can be weighted to T1, T2, or proton density in order to derive signal differences that are intrinsic to the tissue and help characterize the latter. In order to localize the signals coming from the body, gradient magnetic fields of varying magnitude (phase-encoding steps) are switched on and off at appropriate times required to spatially encode MR signal. An MR pulse sequence is a combination of RF pulses and magnetic gradient field alterations controlled by the scanning computer.

To speed up image acquisition, parallel imaging techniques have been developed. These are based on an optimal utilization of redundant information from multiple phased-array coils and allow a reduction in the time-consuming phase-encoding steps required to spatially encode MR signal. High spatial resolution images can be acquired in a markedly shortened time (often by a factor of 2 to 4). Parallel imaging is a mainstay of modern MRA and is used in conjunction with a variety of techniques including contrast-enhanced magnetic resonance angiography (CE-MRA), where it allows rapid imaging during peak arterial contrast opacification. Potential limitations include a reduction in the signal-to-noise ratio.

2. Acquisition Techniques

Knowledge of MRA techniques is essential to the practitioner of MRA. This brief summary outlines the major techniques that the diagnostician should understand. MRA has evolved rapidly since its introduction more than 15 years ago. Initially, non–CE-MRA techniques found their way into clinical routine for imaging vascular morphology. These early approaches can in principle be divided into 2 subgroups (i.e., “black blood” and “bright blood” sequences). Although black blood techniques based on signal voids within vessels containing flowing spins can confirm vessel patency, they remain of limited use in the assessment of vascular morphology. They are currently gaining acceptance, however, for the evaluation of the vascular wall (46).

Bright blood MRA techniques are generally divided into those influenced by the effect of blood flow on signal (time of flight, or TOF) and those based on the flow effect on phase (phase contrast, or PC). Advantages of TOF include a strong signal from blood and that it is completely noninvasive (no contrast agents are needed). However, acquisition times are relatively long, and spin dephasing in areas of flow turbulence results in signal loss that may lead to stenosis overestimation. PC angiography derives image contrast from the differences in the phases accumulated by stationary and moving spins in a magnetic field gradient. The amount of phase accumulated is directly proportional to the flow velocity, allowing quantitative measurement of flow velocities and the discrimination of flow direction. The flow dependence and associated artifacts inherent to these techniques have restricted their clinical use primarily to the extracranial and intracranial arterial system and the portal venous system.

With the advent of high-performance gradient systems, newer MRA strategies have been developed for CE-MRA using gadolinium chelates (47). Intravenous gadolinium chelates are the most commonly employed contrast agents in clinical practice. MRA is based on the combination of rapid 3D imaging and the T1-shortening effect of intravenously infused paramagnetic contrast. These agents greatly shorten the T1 of blood resulting in very bright signal intensity in T1-weighted images. Data acquisition needs to be precisely timed to the arterial phase of the contrast when intraluminal signal is maximal, and be fast enough to minimize motion artifacts and to avoid venous contamination that may hamper image interpretation. Advantages of CE-MRA over older TOF techniques include higher signal-to-noise ratios, robustness irrespective of blood flow patterns or velocities, and faster image acquisition, allowing for the evaluation of larger anatomic segments (from the aortic arch to the circle of Willis). As variants of CE-MRA, time-resolved techniques enable the dynamic visualization of contrast transit through the vasculature and are not dependent on the precise timing of the acquisition, although at the cost of lower spatial resolution. These techniques have been proven to give an extensive and diagnostically accurate evaluation of extracranial, thoracic, abdominal, and peripheral vessels. In many centers, 3D CE-MRA has widely replaced conventional X-ray angiography for the clarification of pathologies in arterial vessels (48).

3. Image Processing and Interpretation

The practitioner of MRA should be knowledgeable about post-processing techniques that are performed at the computer workstation console. Post-processing should include evaluation of the source images from the MRA as well as
MRA is usually performed with 3D coverage of the vessel during a short breath-hold and after intravenous injection of a gadolinium-based contrast agent. Gadolinium has 7 unpaired electrons in its outer shell and hastens T1 relaxation, thereby increasing signal in the area of interest. Gadolinium alone is cytotoxic, but not when combined with a chelating agent. Gadolinium has similar pharmacokinetic properties to iodinated X-ray contrast but with minimal nephrotoxicity and anaphylaxis risk. Several Food and Drug Administration (FDA)-approved gadolinium preparations have been used for over a decade and the safety profile is far more favorable than iodinated contrast. A study of high-dose gadolinium in a population with a high prevalence of baseline renal insufficiency showed no renal failure associated with its administration (49). The rate of allergic reactions to gadolinium is also very low. A survey of 105 centers with more than 700,000 patients receiving the contrast agent has been performed (50). The rate of adverse reactions was very low and was limited to mild nausea, vomiting, and urticaria. The rate of serious allergic reactions was less than 0.01% (50).

On May 23, 2007, the FDA updated a previously issued public health advisory (51) after receiving 90 reports of patients with at least moderate renal dysfunction, gadolinium exposure, and subsequent development of nephrogenic systemic fibrosis (NSF), a dermatologic condition that is characterized by severe and progressive skin induration (52). The proposed association between gadolinium and NSF is strengthened by recent reports of gadolinium isolated from biopsy specimens up to 11 months post-administration in patients with NSF (53). The updated FDA advisory states that exposure to gadolinium-based contrast agents increases the risk for NSF in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73 m²) or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period. The risk, if any, for developing NSF among patients with mild to moderate renal insufficiency or normal renal function is unknown. When recommending or performing an MRI or MRA, carefully weigh the benefits and risks associated with using a gadolinium-based contrast agent in light of recent reports of NSF/nephrogenic fibrosing dermopathy observed following administration of these agents. Choose an alternative imaging method and/or contrast agent whenever possible. 2) Although there are no published data to determine the utility of dialysis to prevent or treat NSF/nephrogenic fibrosing dermopathy, consider prompt dialysis of patients with moderate to end-stage renal disease who undergo an MRI or MRA with a gadolinium-based contrast agent.

5. MRI Safety

MRI is very safe with no short- or long-term ill effects at current field strengths (less than or equal to 3 T). Claustrophobia is problematic in 3% to 7% of patients. A very important safety issue for CMR is the prevention of ferromagnetic objects from entering the scanner area as these will become projectiles. Metallic implants such as hip prostheses, mechanical heart valves, coronary stents, and sternal sutures present no hazard since the materials used are not ferromagnetic (although a local image artifact will result). Care is required in patients with cerebrovascular clips as certain older models remain unsafe in the MR environment. Electronic implants (i.e., infusion or monitoring devices, neurostimulation devices) are still considered absolute contraindications. Pacemakers and implanted cardioverter-defibrillators are considered a contraindication, although recently there have been several case series of patients with pacemakers who successfully underwent MR scanning at 1.5 T with very few changes in pacer function (54–56). This is an area of active investigation and MR-compatible devices are in development.

6. Specific Applications

A. AORTA

An understanding of the utility of MRA in diseases of the aorta is essential. MRA is an excellent technique to define the overall size, shape, and extent of aortic aneurysms. MRI has excellent sensitivity and specificity for the determination of a presence of dissection, and it can cover large fields of view, permitting full assessment of its extent (57,58). It should be recognized that MRI offers certain advantages in aortic dissection, including the ability to characterize thrombus or slow flow in the false lumen by exploiting differences in signal properties. Multiplanar noncontrast imaging can also help delineate intramural hematoma. Practitioners of MRA should know how to use MRI and MRA to demonstrate the characteristic features of penetrating atherosclerotic ulcers (59). MRA of aortic coarctation requires the ability to recognize the site of narrowing, involvement of branch vessels, and the extent of collateral vessels (60). Diagnosticians should understand the use of PC MRI techniques to measure the velocities and flow proximal and distal to the narrowed segments, and estimate the degree of stenosis and the amount of collateral flow (61).

B. UPPER EXTREMITIES

Clinical competence in MRA requires an understanding of its use in the assessment of abnormalities of the brachio-cephalic, subclavian, and axillary arteries. Interpreters of MRA should understand that atherosclerosis is the cause of the majority of stenotic and aneurysmal disease in the arteries of
the upper extremities (62) and that MRA is quite accurate in its diagnostic capacity in this regard (63). Practitioners of MRA should recognize "subclavian steal syndrome" and the ability to depict reversal of flow by PC MRA or TOF MRA with a presaturation pulse first above and then below the vertebral artery (64) as well as the use of CE-MRA to depict the precise site of anatomic obstruction (65). A knowledge of the use of multiple MR techniques in the evaluation of inflammatory arteritis (66) is essential (e.g., Takayasu’s arteritis which has a predilection for involvement of the aortic arch vessels). MRA can demonstrate evidence of giant cell arteritis that can lead to stenoses or aneurysmal dilatation in the thoracic aorta and subclavian and axillary arteries. MR can be useful in the diagnosis of thoracic outlet syndrome as MRI during arm abduction and adduction may confirm vascular compression (67). A competent interpreter of MR of the arterial branches of the aortic arch should be able to recognize and evaluate congenital anomalies such as a vascular ring may cause tracheal or esophageal compression. MRA is an excellent test for evaluation of the arch. Diagnosticians should be familiar with volumetric interpolated breath-hold examination imaging (68) after gadolinium, which can clearly demonstrate the relationship of the trachea, esophagus, and arch vessels.

C. EXTRACRANIAL CEREBROVASCULAR ARTERIES
Knowledge of the signs and symptoms of cerebrovascular disease, common syndromes attributable to specific arterial segments and pathophysiology of stroke are essential elements to the interpretation of MRA. A thorough understanding of cerebrovascular MRA is crucial as it has become an integral part of the routine evaluation for cerebral ischemia. As MRI is used frequently in stroke, MRA can be included with only a few minutes of added scan time. The intracranial carotid artery is easily demonstrated with MRA, and gadolinium-enhanced MRA allows imaging of the entire circulation from the aortic arch to the first division of the major intracranial arteries. 3D reconstructions result in an excellent view of eccentric or highly focal lesions that are not always apparent on the usual anteroposterior and lateral views.

Interpretation of MRA requires a detailed knowledge of the anatomy of the cerebral circulation as well as an understanding of the strengths and weaknesses of vascular imaging with MR in order to interpret normal and abnormal findings. A number of artifacts occur with MRA, and physicians involved in interpretation must understand these pitfalls. Due to the dephasing effects of turbulence, MRA may overestimate the severity of stenosis. MRA is highly specific but identification of significant stenoses generally requires confirmation by another technique. Horizontal segments of the carotid artery, such as the intracranial segment, are less well visualized because of dephasing in the horizontal plane and, thus, a diagnosis of stenosis in this plane is not always reliable. The addition of cerebral MR perfusion contributes complementary information and together with MRA can improve understanding of the clinical significance of arterial lesions.

Physicians interpreting MRA should know that its accuracy is similar to that of CTA for detecting intracranial cerebral aneurysms (69). Sensitivity is greater for larger aneurysms and falls precipitously for aneurysms less than 5 mm. Physicians interpreting MRA should be aware of the difficulty detecting small aneurysms as well as common sites of infundibulum and branch points that can be confused with aneurysms. Pitfalls of MRA, including the effects of movement, turbulence, and slow flow, should be considered. Knowledge of the common sites of aneurysms is important for optimal recognition. Physicians should be well-versed in the use of T1- and T2-weighted and fat-suppressed MRI as well as MRA to detect carotid dissection. It should be recognized that vertebral dissection is not as reliably identified. Knowledge of the use of MRA to detect arterial injury, particularly dissection, is critical in the evaluation of patients with trauma.

D. PELVIC AND LOWER LIMB ARTERIES
A thorough knowledge of techniques employed in peripheral MRA is essential. CE-MRA using a multistation bolus-chase technique in conjunction with dedicated peripheral phased-array coils and extended field of view imaging (500 mm) allow scanning from the diaphragm to the pedal vessels in 3 stations. The addition of parallel imaging technologies, along with novel k-space reordering schemes, especially in the distal stations, has made peripheral runoff MRA significantly more robust, with fewer failed studies and with vastly improved image quality (submillimeter isotropic voxels at the distal stations) (70). Diagnosticians should be cognizant of techniques to reduce venous contamination in the distal stations by the use of centric k-spaced ordered schemes for data acquisition in the distal stations, along with biphasic administration of gadolinium, with a reduced rate of injection for the second bolus (48). The use of venous compression devices at the level of the thighs (with pressures set to less than or equal to 50 mm Hg) also has been shown to delay venous filling (71). The additional incorporation of a time resolved MRA or a dedicated 3D data set at the level of the calf, typically performed prior to a traditional multi-station 3D MRA acquisition, has been shown to result in images devoid of venous contamination and of excellent diagnostic quality (72,73). Physicians should recognize the high sensitivity and specificity of MRA for the diagnosis of PAD (74) and the utility of MRA for assessing graft patency, as well as inflow and outflow disease (75).

Practitioners of vascular MR should understand the use of additional vessel wall-specific sequences used in conjunction with MRA, particularly in the abdomen, which may help delineate aneurysms, presence of intramural clot, dissection, and atherosclerosis with only a minimal increase in scan time. Sequences that may be chosen for this purpose include dark-blood half Fourier acquisition single-shot
turbo spin-echo images, fat-saturated volumetric T1 gradient echo sequence, or a traditional inversion recovery prepared gradient echo sequence, especially after contrast.

E. RENAL ARTERIES

Practitioners of MRA should appreciate that renal artery stenosis is an important cause of secondary hypertension. The knowledge required to perform renal MRA includes an understanding of its ability to evaluate the renal arteries and accessory renal arteries directly (76), establish the site and severity of stenoses, and their hemodynamic significance (77), measure kidney size and parenchymal thickness, and identify perirenal and aortic pathology. The specialist should be able to recognize and identify the causes of renal artery stenosis, which include atherosclerotic disease, fibromuscular dysplasia, arterial dissection, and extrinsic compression of renal arteries. Aneurysms involving the main renal arteries should be identified; however, the smaller intraparenchymal aneurysms seen in polycystic kidney disease may not be as reliably detected. Physicians should comprehend the pulse sequences used to assess the renal arteries including 2D or 3D TOF, PC imaging, and CE-MRA. The use of contrast allows for a more accurate evaluation of tortuous vessels, distal vessels, and smaller accessory renal arteries and can aid in the diagnosis of fibromuscular dysplasia. The MRA interpreters should have knowledge of the use of the technique in renal donors or after renal transplantation. The expert should be able to use post-processing techniques including subvolume MIPs encompassing each renal artery in coronal, oblique, and axial planes (78).

F. MESENTERIC ARTERIES

Physicians should recognize that unlike acute mesenteric ischemia, chronic mesenteric ischemia due to atherosclerotic disease is well-suited for evaluation by MRA. Knowledge of the appropriate pulse sequence to use for this disorder is essential. Although TOF (79) and PC MRA (80) can be used, CE-MRA is more robust and faster, especially when parallel imaging techniques are applied (47,81). The CE-MRA techniques are highly accurate and compare favorably to catheter-based approaches (82). The specialist should also be able to recognize normal anatomy and its variations as well as surgical anatomy. The causes of acute and chronic mesenteric ischemia need to be recognized and specific etiologies such as atherosclerosis, arterial and venous thrombosis, external compression, and vasculitis should be identified. The specialist should also be able to identify pseudo-stenosis and aneurysmal disease. Practitioners of MRA should be able to recognize anatomic variations and celiac artery pseudo-stenosis, which is commonly caused by extrinsic compression by the median arcuate ligament. MRA can also be useful for evaluation after a revascularization procedure and for examining the extent and nature of external compression on mesenteric arteries or veins.

G. MR VENOGRAPHY

Knowledge of superior vena cava (SVC) and IVC anatomy, as well as potential causes of compression or obstruction (tumor, thrombus, etc.), is essential to the interpreter of MRA (83). It is important to recognize benign systemic venous anomalies such as a persistent left SVC with or without azygous continuation of the IVC (84). In the cerebral circulation, knowledge of typical clinical syndromes of venous infarction and the imaging characteristics of venous infarcts that distinguish them from arterial disease is essential to proper interpretation. MR venography visualizes the major venous sinuses and detailed knowledge of venous anatomy is necessary to identify occlusive disease associated with infarction. Physicians should have knowledge of common congenital variants that might be misinterpreted as a pathological venous occlusion. They should understand that mesenteric venous occlusion is an uncommon but important cause of mesenteric ischemia. Practitioners of MRA should understand the potential of multiphase dynamic CE imaging (85) for examination of the venous system.

H. WHOLE BODY MRA

There is a known relationship between the presence of significant stenoses in one vascular bed with asymptomatic disease in another (86). Thus, practitioners of MRA should appreciate whole body MRA as a potential screening tool. This has been performed by combining the bolus-chase approach with a rolling table platform (87). Knowledge of techniques to optimize whole body MRA is important including the use of integrated parallel acquisition techniques to increase spatial and temporal resolution and reduce venous contamination in the abdomen and infrapopliteal region, without an increase in acquisition time (88). However, the clinical value of whole body MRA has not yet been systematically tested in large populations.

Formal Training to Achieve Competence

Cognitive skills required to demonstrate competence in vascular MR are summarized in Table 5. The physician should be able to demonstrate competence in the theoretical principles of MRI. Trainees should receive didactic lectures from a qualified MR-trained physician and/or physicist on the basic physics of MR. A thorough understanding of contrast injection methods and contrast kinetics in patients will be required. In particular, knowledge is needed in appropriate bolus timing approaches that may be different for various vascular beds. A thorough knowledge and understanding of vascular anatomy is required. Characteristics of a vessel in health and disease by traditional angiographic imaging methods (X-ray contrast angiography) will provide a significant background for application to MRA of the peripheral vessels. An understanding of basic concepts in vessel physiology is vital for an angiographer interpreting a stenosis in any vascular bed and basic training should be part of any formal training program.
There are several potential pathways to achieve competence in vascular MR including formal fellowships and alternative pathways, both with accompanying CME. The training achieved may allow a practitioner to either interpret or, depending on the expertise achieved, interpret and teach others the competencies in vascular MR. Table 5 lists the cognitive skills required for competence in vascular MR.

1. Formal Fellowship

Formal training in vascular MR may be undertaken as part of cardiovascular fellowship (see the latest COCATS guidelines for CMR) (1). The didactic training experience achieved should parallel that described in the COCATS guidelines for Level 2 trainees. A basic understanding of MR physics and clinical applications should be obtained. Trainees should actively participate in daily MR study interpretation under the direction of a Level 2 or 3 (preferred) CMR-qualified physician. For all studies in which other vascular imaging data are available, such information should be correlated with MR data. This should include at least 50 cases of vascular MR, for which the trainee is present during the scan, ideally as the primary operator and the primary interpreter.

2. Alternative Pathways

Alternative pathways (Table 6) include at least 4 weeks spent with a practitioner of vascular MR who has the prior training experience. For those individuals who have achieved Level 2 or 3 training in CMR, there is no specific time requirement. With either pathway, at least 50 cases of vascular MR should be performed to demonstrate competence, ideally for which the trainee is present during the scan and is the primary operator/interpreter. These cases should include the variety of cases as previously outlined. An additional 100 cases from teaching files, case studies, CDs/DVDs, or CME courses also should be reviewed.

Maintaining Expertise

As is true for many other procedures, a minimum number of cases are necessary to ensure continued proficiency in quality of care.

1. Clinical Experience

Maintenance of vascular MR expertise requires both ongoing CME and regular performance and interpretation of vascular MR examinations. Physicians should periodically

---

**Table 5. Cognitive Skills Required for Competence in Vascular MR**

<table>
<thead>
<tr>
<th>Knowledge</th>
<th>Cognitive Skills Required</th>
</tr>
</thead>
<tbody>
<tr>
<td>General</td>
<td>Hardware and physical principles of MR</td>
</tr>
<tr>
<td></td>
<td>Scanning principles and scanning modes for noncontrast- and contrast-enhanced vascular imaging</td>
</tr>
<tr>
<td></td>
<td>Principles of intravenous contrast administration for optimal vascular imaging</td>
</tr>
<tr>
<td></td>
<td>Principles of image post-processing and appropriate applications</td>
</tr>
<tr>
<td></td>
<td>Safety issues surrounding MR, including contraindications</td>
</tr>
<tr>
<td>Vascular anatomy</td>
<td>Normal anatomy of the aorta, brachiocephalic, cerebrovascular, pelvic and lower extremity, renal, and mesenteric arteries</td>
</tr>
<tr>
<td></td>
<td>Normal anatomy of the SVC and IVC, cerebrovascular, pelvic, lower extremity, renal, and mesenteric veins</td>
</tr>
<tr>
<td>Vascular pathology</td>
<td>Congenital anomalies, aneurysm, dissection, occlusion, and stenosis of the aorta, brachiocephalic, cerebrovascular, pelvic and lower extremity, renal, and mesenteric arteries</td>
</tr>
<tr>
<td></td>
<td>Thrombosis, compression, and occlusion of the superior and inferior vena cava, cerebrovascular, pelvic, lower extremity, renal, and mesenteric veins</td>
</tr>
</tbody>
</table>

**Table 6. Alternative Pathways for Competence in Vascular MR**

<table>
<thead>
<tr>
<th>Pathway</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial experience*</td>
<td>• Level 2 or 3 CMR trained OR• 4 weeks of dedicated time with a qualified practitioner of vascular MR</td>
</tr>
<tr>
<td></td>
<td>• Level 2 or 3 CMR trained OR• 4 weeks of additional equivalent experience through supervised time, CME, other courses, case studies, CD/DVD training</td>
</tr>
<tr>
<td>Minimum number of mentored exams</td>
<td>• Mentored interpretation of 50 cases of vascular MR, ideally covering a broad range of vascular beds</td>
</tr>
<tr>
<td>Additional case reviews</td>
<td>• 100 cases from teaching files, case studies, CDs/DVDs, CME courses</td>
</tr>
</tbody>
</table>

---

*If one has obtained Level 2 or 3 competence in CMR, the time requirement is waived.
CME = continuing medical education; CMR = cardiovascular magnetic resonance; CT = computed tomography; MR = magnetic resonance.
attend postgraduate courses and workshops that focus on vascular MR, especially those that emphasize new and evolving techniques and developments. In addition, physicians should seek to compare the quality, completeness, and results of their own examinations with those presented at scientific meetings and in professional publications. If competence is assured primarily on the basis of continuing experience, a minimum of 50 examinations per year is recommended in order to maintain the physician’s skills. Because a physician’s practice or location may preclude this method, continued competency can also be assured through monitoring and evaluation that indicates acceptable technical success, accuracy of interpretation, and appropriateness of evaluation.

2. CME

Thirty hours of CME over 3 years in CMR or related fields are required to maintain expertise in vascular MR.

REFERENCES


APPENDIX 1: AUTHOR RELATIONSHIPS WITH INDUSTRY—ACCF/AHA 2007 CLINICAL COMPETENCE STATEMENT ON VASCULAR IMAGING WITH COMPUTED TOMOGRAPHY AND MAGNETIC RESONANCE

<table>
<thead>
<tr>
<th>Name</th>
<th>Consultant</th>
<th>Research Grant</th>
<th>Scientific Advisory Board</th>
<th>Speakers’ Bureau</th>
<th>Steering Committee</th>
<th>Stock Holder</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Matthew J. Budoff</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>GE Healthcare</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dr. Zahi A. Fayad</td>
<td>None</td>
<td>NIH</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Philips–medical research equipment support</td>
</tr>
<tr>
<td>Dr. Victor A. Ferrari</td>
<td>None</td>
<td>GlaxoSmithKline</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dr. Corey Goldman</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Merck</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dr. Christopher M. Kramer</td>
<td>Novartis</td>
<td>Astellas</td>
<td>None</td>
<td>GE Healthcare</td>
<td>None</td>
<td>None</td>
<td>Siemens–research equipment support</td>
</tr>
<tr>
<td>Dr. John R. Lesser</td>
<td>Vital Images</td>
<td>Vital Images</td>
<td>None</td>
<td>Siemens</td>
<td>None</td>
<td>None</td>
<td>Merck–research support</td>
</tr>
<tr>
<td>Dr. Edward T. Martin</td>
<td>GE Healthcare</td>
<td>GE Healthcare</td>
<td>None</td>
<td>GE Healthcare</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dr. Sanjay Rajagopalan</td>
<td>Genzyme</td>
<td>None</td>
<td>None</td>
<td>Genzyme</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dr. John P. Reilly</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dr. George P. Rodgers</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dr. Lawrence Wechsler</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

This table represents the relationships of committee members with industry that were reported orally at the initial Writing Committee meeting and updated in conjunction with all meetings and conference calls of the Writing Committee during the document development process. It does not necessarily reflect relationships with industry at the time of publication.

APPENDIX 2: PEER REVIEWERS RELATIONSHIPS WITH INDUSTRY—ACCF/AHA 2007 CLINICAL COMPETENCE STATEMENT ON VASCULAR IMAGING WITH COMPUTED TOMOGRAPHY AND MAGNETIC RESONANCE

<table>
<thead>
<tr>
<th>Name</th>
<th>Representation</th>
<th>Consultant</th>
<th>Research Grant</th>
<th>Scientific Advisory Board</th>
<th>Speakers’ Bureau</th>
<th>Steering Committee</th>
<th>Stock Holder</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Martin R. Prince</td>
<td>Official–AHA</td>
<td>Guerbet</td>
<td>None</td>
<td>Guerbet</td>
<td>Berlex</td>
<td>None</td>
<td>Epix</td>
<td>None</td>
</tr>
<tr>
<td>Dr. Geoffrey Rubin</td>
<td>Official–AHA</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>GE Medical</td>
<td>None</td>
</tr>
<tr>
<td>Dr. Chittur Sivaram</td>
<td>Official–ACC Board of Governors</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Phillips</td>
<td>None</td>
</tr>
<tr>
<td>Dr. Allen Taylor</td>
<td>Official–ACC Board of Governors</td>
<td>Merck</td>
<td>KOS</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Siemens</td>
<td>None</td>
</tr>
<tr>
<td>Dr. Kim Williams</td>
<td>Official–ACC Board of Trustees</td>
<td>Astellas</td>
<td>GE Medical</td>
<td>None</td>
<td>GE Medical</td>
<td>GE Medical</td>
<td>3F Therapeutics–Data and Safety Monitoring Board</td>
<td>None</td>
</tr>
<tr>
<td>Name</td>
<td>Representation</td>
<td>Consultant</td>
<td>Research Grant</td>
<td>Scientific Advisory Board</td>
<td>Speakers’ Bureau</td>
<td>Steering Committee</td>
<td>Stock Holder</td>
<td>Other</td>
</tr>
<tr>
<td>----------------------</td>
<td>-----------------------------------------------------</td>
<td>---------------------------------</td>
<td>----------------</td>
<td>---------------------------</td>
<td>------------------</td>
<td>--------------------</td>
<td>--------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>Dr. David E. Allie</td>
<td>• Organizational–Society of Cardiovascular Computed Tomography</td>
<td>• Bracco</td>
<td>None</td>
<td>• Bracco</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Toshiba</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Amjad AlMahameed</td>
<td>• Organizational–Society for Vascular Medicine and Biology</td>
<td>None</td>
<td>None</td>
<td>• GlaxoSmith-Kline</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Joerg Barkhousen</td>
<td>• Organizational–Society for Cardiovascular Magnetic Resonance</td>
<td>• Guerbet</td>
<td>None</td>
<td>• Guerbet</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• MR Innovation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Schering</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Leonardo C. Clavijo</td>
<td>• Organizational–Society for Vascular Medicine and Biology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dr. James B. Froehlich</td>
<td>• Organizational–Society for Vascular Medicine and Biology</td>
<td>• Pfizer</td>
<td>None</td>
<td>• Pfizer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Sanofi-Aventis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Harvey Hecht</td>
<td>• Organizational–Society of Atherosclerosis Imaging and Prevention</td>
<td>None</td>
<td>• Philips</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dr. John Hodgson</td>
<td>• Organizational–Society for Cardiovascular Angiography and Interventions</td>
<td>• Volcano</td>
<td>• Boston</td>
<td>• Boston</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• Bioinfo Accelerator</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Scientifcal</td>
<td></td>
<td>Scientifcal</td>
<td></td>
<td></td>
<td></td>
<td>Volcano</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GE Medical</td>
<td></td>
<td>GE Medical</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>RADI Medical</td>
<td></td>
<td>Pfizer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Volcano</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Scott Kinlay</td>
<td>• Organizational–Society for Vascular Medicine and Biology</td>
<td>• Merck</td>
<td>• Pfizer</td>
<td>• Pfizer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Pfizer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Robert Schwartz</td>
<td>• Organizational–Society for Cardiovascular Angiography and Interventions</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• Vital Images</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dr. Norbert Wilke</td>
<td>• Organizational–Society of Cardiovascular Computed Tomography</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dr. Peter Fail</td>
<td>• Content–Individual Reviewer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• Foxhollow Technologies</td>
</tr>
<tr>
<td>Dr. Scott Flamm</td>
<td>• Content–Individual Reviewer</td>
<td>None</td>
<td>• Philips</td>
<td>• Vital Images, Inc.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Siemens</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Tyco</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Thomas Gerber</td>
<td>• Content–Individual Reviewer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dr. Paolo Raggi</td>
<td>• Content–Cardiovascular Imaging Committee</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>
This table represents the relationships of peer reviewers with industry that they reported as relevant to this topic. It does not necessarily reflect relationships with industry at the time of publication. Participation in the peer review process does not imply endorsement of the document. Names are listed in alphabetical order within each category of review.

<table>
<thead>
<tr>
<th>Name</th>
<th>Representation</th>
<th>Consultant</th>
<th>Research Grant</th>
<th>Scientific Advisory Board</th>
<th>Speakers’ Bureau</th>
<th>Steering Committee</th>
<th>Stock Holder</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. James Thomas</td>
<td>Content–Cardiovascular Imaging Committee</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dr. Samuel Wann</td>
<td>Content–Individual Reviewer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Ms. Deborah Wesley</td>
<td>Content–Individual Reviewer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

ACCF/AHA Clinical Competence Statement: Vascular CT/MR

September 11, 2007:1097–114